

Results of Meeting

PainChek® Ltd (ASX: PCK) (“PainChek®” or “the Company”), developer of the world’s first AI-powered pain assessment and monitoring application, is pleased to announce the results of its Annual General Meeting held today.

All resolutions put to shareholders today were passed by the required majority. Details of the resolutions, the proxies, and the votes cast on the poll in respect of the resolutions are set out in the attached results. The effective date of the securities consolidation is 26 November 2025.

This announcement has been authorised for release by the Board

For more information:

Natalie Climo

Company Secretary, PainChek

natalie.climo@boardroomlimited.com.au

02 8016 2875

Philip Daffas

CEO, PainChek

philip.daffas@painchek.com

0406 537 235

About PainChek

[PainChek®](#) is the world’s first regulatory-cleared medical device for the assessment of pain, enabling best-practice pain management for people living with pain in any environment, from those who cannot reliably self-report their pain, those who can, and for those whose ability to self-report their pain fluctuates.

The PainChek® Adult app is available on smartphones and tablets and combines PainChek’s AI pain assessment tool, which intelligently automates the multidimensional pain assessment process, with the Numerical Rating Scale (NRS). This hybrid functionality allows accurate, consistent pain assessment at the point of care, and for care to be considered in PainChek’s detailed reporting suite, PainChek® Analytics.

Globally, PainChek® has attained regulatory clearance as a medical device in Australia, USA, Canada, the European Union, New Zealand, Singapore, Malaysia, and the United Kingdom.

PainChek® has contracts with over 1,900 aged care facilities, with more than 12,000,000 digital pain assessments conducted to date, and is trusted by thousands of nurses, carers, and clinicians.

Using PainChek®, facilities can:

- Ensure greater consistency, continuity, and diagnostic certainty in pain assessment and management by decreasing subjectivity and removing unintentional assessor bias
- Streamline the pain assessment process for time-poor carers, with access to the PainChek® tool, the NRS, pain trends, and charting in one solution

- Simplify record-keeping and documentation to demonstrate compliance and support funding claims, with all historical pain assessment data in one place
- Enhance engagement with GPs and allied healthcare professionals

Clinical studies conducted in Australian and UK residential aged care centres have been published in various peer-reviewed journals including the [Journal of Alzheimer's Disease](#). An article in [BMC Geriatrics](#) indicates that PainChek® is a valid and reliable instrument to assess the presence and severity of pain in people with moderate-to-severe dementia living in aged care. Further information on clinical studies can be found [here](#).

PainChek® has successfully supported accurate pain assessment and management for thousands of adults worldwide living with dementia, disability, or other conditions impacting their ability to self-report pain. Building on the success of this technology, the clinically validated [PainChek® Infant app](#) identifies and detects six facial action units indicative of pain in infants aged one month to 12 months.

The need for PainChek as a best-practice pain management solution also extends to older people living at home and with access to home care packages that enable long-term home living. PainChek is expanding into home care by partnering with home care and disability service providers.

For more information, visit: <https://painchek.com>

PainChek Ltd
Annual General Meeting
Wednesday, 26 November 2025
Results of Meeting

The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2.

Resolution details	Resolution Type	Instructions given to validly appointed proxies (as at proxy close)				Number of votes cast on the poll (where applicable)			Resolution Result Carried / Not Carried	If s250U applies
		For	Against	Proxy's Discretion	Abstain	For	Against	Abstain*		
1. Adoption of Remuneration Report	Ordinary	314,502,419 89.30%	7,528,030 2.14%	30,172,314 8.57%	3,153,048	349,874,732 97.89%	7,528,030 2.11%	3,153,048	Carried	NO
2. Re-Election of Director – John Murray	Ordinary	320,892,089 76.91%	47,601,820 11.41%	48,745,397 11.68%	399,512	387,760,328 89.07%	47,601,820 10.93%	399,512	Carried	NA
3. Re-Election of Director – Ross Harricks	Ordinary	320,892,089 76.91%	47,601,820 11.41%	48,745,397 11.68%	399,512	376,519,655 88.78%	47,601,820 11.22%	11,640,185	Carried	NA
4. Approval to issue 10% of Placement Capacity (Special Resolution)	Special	365,239,130 87.52%	5,429,383 1.30%	46,649,913 11.18%	320,392	430,011,885 98.75%	5,429,383 1.25%	320,392	Carried	NA
5. Ratification of Prior Issue of Placement Shares	Ordinary	258,273,665 83.81%	2,671,989 0.87%	47,212,413 15.32%	410,392	323,608,920 99.18%	2,671,989 0.82%	410,392	Carried	NA
6. Approval to Issue Placement Shares to Director Philip Daffas	Ordinary	291,951,177 74.85%	49,344,798 12.65%	48,751,897 12.50%	27,590,946	358,825,916 87.91%	49,344,798 12.09%	27,590,946	Carried	NA
7. Approval to Issue Placement Shares to Director Cynthia Payne	Ordinary	316,409,087 76.01%	50,918,270 12.23%	48,967,239 11.76%	191,219	381,816,998 88.23%	50,918,270 11.77%	191,219	Carried	NA
8. Issue of Performance Rights to Director Philip Daffas	Ordinary	271,652,613 72.98%	51,596,070 13.86%	48,967,239 13.16%	29,537,177	325,819,851 86.33%	51,596,070 13.67%	29,537,177	Carried	NA
9. Issue of Performance Rights to Director John Murray	Ordinary	271,112,635 72.88%	52,150,854 14.02%	48,751,897 13.10%	2,426,767	325,064,531 86.17%	52,150,854 13.83%	2,426,767	Carried	NA
10. Issue of Performance Rights to Director Cynthia Payne	Ordinary	270,897,293 72.82%	52,150,854 14.02%	48,967,239 13.16%	2,426,767	325,064,531 86.17%	52,150,854 13.83%	2,426,767	Carried	NA
11. Issue of Performance Rights to Director Adam Davey	Ordinary	270,130,013 72.76%	52,133,161 14.04%	48,984,932 13.19%	17,926,763	324,314,944 86.15%	52,133,161 13.85%	17,926,763	Carried	NA
12. Issue of Performance Rights to Director Ross Harricks	Ordinary	270,897,293 72.44%	52,150,854 13.94%	50,934,751 13.62%	459,255	327,032,043 86.25%	52,150,854 13.75%	459,255	Carried	NA
13. Consolidation of Share Capital	Ordinary	362,068,509 86.74%	8,630,054 2.07%	46,720,255 11.19%	220,000	426,911,606 98.02%	8,630,054 1.98%	220,000	Carried	NA
14. Approval of Long-Term Incentive Plan	Ordinary	309,262,304 83.42%	12,498,023 3.37%	48,967,239 13.21%	17,905,544	363,429,542 96.68%	12,498,023 3.32%	17,905,544	Carried	NA

* Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.